Objectives-To assess the relationship between the approval of trials by a r
esearch ethics committee (REC) and the fact that informed consent from part
icipants (ICP) was obtained, with the quality of study design and methods.
Design-Systematic review using a standardised checklist.
Main measures-Methodological and ethical issues of all trials published bet
ween 1993 and 1995 in the New England Journal of Medicine, the Lancet, the
Journal of the American Medical Association and the British Medical Journal
were studied. In addition, clinical trials conducted in Spain and publishe
d by at least one Spanish author during the same period in any other journa
l were also included.
Results-We studied the published articles of 767 trials and found the follo
wing indicators of lower methodological quality to be independent predictor
s for failure to disclose REC approval or ICP: absence of concealment of al
location, lack of justification for unblinded trials, not using a treatment
for the patients in the control group, absent information on statistical m
ethods, not including sample size estimation, not establishing the rules to
stop the trial, and omitting the presentation of a baseline comparison of
groups
Conclusion-Trials of higher methodological and scientific quality were more
likely to provide information about their ethical aspects.